| Name | Title | Contact Details |
|---|---|---|
Mark Verbeek |
Controller and Director of Information Technology | Profile |
Mary Calvano |
Senior Vice President of Marketing and Innovation | Profile |
Mercy Retirement and Care Center, a nonprofit organization, has been providing quality compassionate care and services to older adults for more than 130 years. Supportive residential, assisted living, dementia care and skilled nursing programs are offered
Neurosurgery and Spine Consultants of East Tennessee is a Knoxville, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Spray-Tek is a Middlesex, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Welcome to the Alliance for Positive Health! We are a community based organization dedicated to improving lives impacted by HIV/AIDS and other chronic illnesses. For over 30 years the Alliance for Positive Health has modeled client centered care and provided skills to help those we serve make informed decisions. Please explore this website to find out about the wide range of support, services and interventions we provide to improve the health of our community. At the Alliance for Positive Health, we work with those who face barriers to accessing health care and social services and strive to reduce health disparities. Our clients` diagnoses are often complicated by stigma, addiction, poverty, homelessness, incarceration or mental illness – and these are the factors which also place them at risk infection with HIV, Hepatitis C and other Sexually Transmitted Diseases.
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.